VolitionRx Reports Third Quarter 2025 Financial Results and Business Developments

VolitionRx Limited: Third Quarter 2025 Financial Results and Business Update

On November 13, 2025, VolitionRx Limited (NYSE AMERICAN: VNRX), a leading multi-national company in epigenetics, presented its financial results and business performance for the third quarter ending September 30, 2025. With an eye on advancing diagnostic technologies, the company hosted a conference call on November 14, 2025, to delve deeply into these results.

Cameron Reynolds, the President and Group Chief Executive Officer of Volition, shared optimistic insights into the company’s strategic initiatives in 2025. This year, Volition focused on commercializing its innovative Nu.Q® platform within the human diagnostics market. The company proudly reported the signing of two significant human-related agreements this quarter: a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome in partnership with Werfen, and a Co-Marketing and Services Agreement with Hologic. Both these entities are powerful, globally recognized leaders in their respective markets, which positions Volition favorably.

Reynolds also mentioned engaging discussions with approximately ten of the top diagnostic and liquid biopsy firms worldwide. These discussions are at varied stages encompassing due diligence, technology transfer, evaluation of clinical samples, and contract negotiations, indicating strong potential for future collaborations.

Moreover, the emergence of compelling clinical evidence further signifies the expansive applicability of the Nu.Q® technology in critical domains such as cancer and sepsis detection. This recognition aligns with the ongoing interest within the pharmaceutical sector, particularly regarding epigenetic drug development.

In the last few months, Volition has made notable strides in research publications and anticipates releasing more peer-reviewed studies in the upcoming quarters. Among these is an expected report on their breakthrough Capture-Seq™ technology, which focuses on the capability to concentrate chromatin fragments, thereby enhancing tumor DNA detection in liquid biopsies.

The roadmap for Volition is ambitious, aiming to secure a variety of licensing agreements in human diagnostics that reflect its successful ventures in the veterinary market. By implementing varied deal structures, the company anticipates different revenue streams, including upfront payments, milestone payments, and ongoing revenue.

In terms of financial performance for the third quarter, Volition reported a revenue of $0.6 million, marking a remarkable growth of 32% compared to the same period last year. Furthermore, the operating expenses demonstrated an encouraging decrease of 10% year-on-year, alongside a net loss reduction of 8% for the quarter and 20% for the year to date. The net cash utilized for operating activities also saw a significant 33% decrease compared to the prior year’s quarter.

Subsequent to the quarter's end, Volition successfully acquired approximately $6.1 million in net proceeds from a public offering, contributing positively to its financial positioning.

The upcoming conference call, scheduled for November 14, aims to provide a comprehensive overview of the progress made in Q3 along with insights into forthcoming goals. Company leaders, including Louise Batchelor, Group Chief Marketing Communications Officer, Terig Hughes, Group Chief Financial Officer, and Dr. Jake Micallef, Chief Scientific Officer will present critical updates from the quarter and projected milestones. Intriguingly, a live audio webcast of this call will be available, allowing broader accessibility for stakeholders.

Founded with a mission centered on enhancing the science of epigenetics, VolitionRx is dedicated to improving outcomes for individuals and animals afflicted by life-changing diseases through earlier detection and monitoring methodologies. Its endeavors encompass the development of simple, cost-effective blood tests targeting various diseases, including certain cancers and conditions associated with NETosis, such as sepsis. The significance of early detection cannot be overstated, as it not only has the potential to prolong life but also to enhance the quality of that life.

With research and development facilities in Belgium, innovation labs in the U.S., and an office in London, VolitionRx is well-positioned to pursue its ambitious goals. The firm remains committed to maintaining comprehensive transparency with its stakeholders as it charts the course for sustainable growth in the vital diagnostic landscape.

For media inquiries, contact: Louise Batchelor at +44 (0)7557 774620 or for investor relations, Jeremy Feffer at +1-212-915-2568.